Skip to content
value.today

JumpCode Genomics, Inc.

Total raised
$39 M
5 rounds on record
Latest round
$3 M
Aug 2024
First round on record
Sep 2018
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of JumpCode Genomics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2024$3 MNo. 5$2 to $10 million

JumpCode Genomics, Inc.: Raise no. 5, Aug 2024

Investors in this round

8 investors had bought by the notice of Aug 22, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $11 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Michael Salter · Executive Officer, Director
  • Court Michael Turner · Director
  • Joseph Michael Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Totals include amounts receivable upon the exercise of warrants. Such warrants have not yet been exercised.”

Signed by David Michael Salter, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 22, 2024. Read the notice at the SEC.

equity, optionsSEC
Apr 2023$9 MNo. 4$2 to $10 million

JumpCode Genomics, Inc.: Raise no. 4, Apr 2023

Investors in this round

7 investors had bought by the notice of May 9, 2023: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $16 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brandon Poe · Executive Officer
  • Yaron Hakak · Executive Officer, Director
  • Court Turner · Director
  • Dan Kidle · Director
  • Frank Witney · Director
  • Kirk Malloy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Totals include amounts receivable upon the exercise of issued and issuable warrants.”

Signed by Yaron Hakak, Chief Executive Officer. Source: SEC Form D, newest notice filed May 9, 2023. Read the notice at the SEC.

equity, optionsSEC
Dec 2020$21 MNo. 3$10 to $50 million

JumpCode Genomics, Inc.: Raise no. 3, Dec 2020

Investors in this round

5 investors had bought by the notice of Dec 26, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Keith Brown · Executive Officer
  • Yaron Hakak · Executive Officer, Director
  • Dan Kidle · Director
  • Frank Witney · Director
  • Kevin Li · Director
  • Kirk Malloy · Director
  • Michael Liang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Yaron Hakak, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 26, 2020. Read the notice at the SEC.

equitySEC
Jan 2020$2 MNo. 2Under $2 million

JumpCode Genomics, Inc.: Raise no. 2, Jan 2020

Investors in this round

1 investor had bought by the notice of Feb 11, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Keith Brown · Executive Officer, Director
  • Eugene Chen · Director
  • Joel Rotroff · Director
  • Kevin Li · Director
  • Kirk Malloy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Keith Brown, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 11, 2020. Read the notice at the SEC.

equitySEC
Sep 2018$4 MNo. 1$2 to $10 million

JumpCode Genomics, Inc.: Raise no. 1, Sep 2018

Investors in this round

4 investors had bought by the notice of Sep 12, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Keith Brown · Executive Officer, Director
  • Eugene Chen · Director
  • Joel Rotroff · Director
  • Kirk Malloy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$1,011,275.14 cancellation of indebtedness; $2,499,999.81 of new cash”

Signed by Keith Brown, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 12, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • JumpCode Genomics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2024).

    SEC Form D · Aug 2024

  • The industry group it chose in its notices: Other.

    SEC Form D · Aug 2024

That is all the official record says: JumpCode Genomics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of JumpCode Genomics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by JumpCode Genomics, Inc.
NameRoleNamed in
David Michael SalterExecutive officerAug 2024
Brandon PoeExecutive officerMay 2023
Yaron HakakExecutive officerMay 2023
Keith BrownExecutive officerDec 2020
Court Michael TurnerDirectorAug 2024
David Michael SalterDirectorAug 2024
Joseph Michael LeeDirectorAug 2024
Court TurnerDirectorMay 2023
Dan KidleDirectorMay 2023
Frank WitneyDirectorMay 2023
Kirk MalloyDirectorMay 2023
Yaron HakakDirectorMay 2023
Kevin LiDirectorDec 2020
Michael LiangDirectorDec 2020
Eugene ChenDirectorFeb 2020
Joel RotroffDirectorFeb 2020
Keith BrownDirectorFeb 2020